![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medical Solutn | LSE:MLS | London | Ordinary Share | GB0009739649 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.72 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Medical Solutions PLC 11 February 2008 For further information, please contact: Medical Solutions plc Nick Ash Managing Director Tel: 0115 973 9010 www.medical-solutions.co.uk Bishopsgate Communications Ltd Nick Rome/Gemma O'Hara Tel: 0207 562 3350 www.bishopsgatecommunications.com 11 February 2008 Medical Solutions plc ("Medical Solutions" or the "Company") EXCLUSIVE DISTRIBUTION AGREEMENT Medical Solutions enters an exclusive UK agreement with Empire Genomics, LLC as a distributor and service provider for ACCUArray genotyping The Board of Medical Solutions plc (LSE: MLS), the provider of expert, quality DNA sequencing and genotyping services to the healthcare, pharma biotech and life sciences research sectors, is pleased to announce that it will partner with Empire Genomics, Inc. to be the exclusive UK distributor and service provider for its ACCUArray array comparative genomic hybridization ("aCGH") genotyping technology. In addition to distributing the product, Medical Solutions will also offer the genotyping service from its laboratories in Nottingham, which will include in-house bioinformatics analysis and support. HIGHLIGHTS * Exclusive distributor and service provider in the UK; * Medical Solutions to offer both Human and Mouse ACCUArray aCGH as a product and also provide the genotyping service that will include in-house bioinformatic analysis; * Novel DNA array for pre-natal, cancer and pharmacogenetic testing with diagnostic and research applications; * Enhanced portfolio of genomic products and services provided in GLP, GCP and CPA accredited laboratories. The addition of Empire Genomics ACCUArray will complement Medical Solutions existing portfolio of genomic products and contract research services including DNA clones and genomic analyses. The assay has clinical diagnostic applications for the healthcare community and can be used for pharmacogenetic testing by companies in the pharma biotech sector. This further demonstrates the Company's commitment to be a market leader in the UK for the provision of expert, quality laboratory services and genomic reagents to the healthcare and life science research sectors. Dr Tom Weaver, Commercial Director for Medical Solutions, said "The diagnostic capability of this assay is of particular interest to those groups in the healthcare community involved in cytogenetic and pre and post natal testing. ACCUArray aCGH provides a tremendous tool for the identification of genetic aberrations linked with a number of diseases and conditions such as cancer, autism, mental health problems including Alzheimer's, several congenital abnormalities and certain syndromes including Down Syndrome". Dr Weaver added "The Empire Genomics aCGH kit, provides a high resolution and robust screening procedure for researchers, clinicians and pharmacologists. The supporting software provides data analysis within 24 hours in a concise and accessible format." - ends - About Medical Solutions Medical Solutions is a leading provider of expert, quality services and products to the healthcare, pharma biotech and life science research sectors. Its Healthcare operations provide screening products and reference laboratory diagnostic testing services for cancer and other diseases and additional predictive testing for treatment optimisation for clinicians and patients. Pharma Biotech Services offers support for early stage therapeutic development, offering a "one-stop shop" from tissue pathology, immunohistochemistry, sophisticated image analysis, biomarker determination and assay development to pharmacogenomics including genotyping and gene expression analysis. The Life Science Research services provide core laboratory research support from conceptualization to implementation, calling upon a wide ranging of cutting-edge technology platforms including and an online catalogue of biomolecular tools. This incorporates DNA sequencing, whole genome amplification and a comprehensive library of genomic reagents and clones including cDNA and RNAi. The group has its headquarters in Nottingham, UK where it operates state of the art reference laboratory facilities, with additional UK laboratory facilities in Cambridge and Oxford. Medical Solutions is CPA, GLP and GCP accredited and is licensed by the Human Tissue Authority. Further information is available from www.medical-solutions.co.uk About Empire Genomics Empire Genomics, based in Buffalo, New York, utilises proprietary techniques to identify and quantify chromosomal abnormalities. Specifically the company has evolved array-based Comparative Genomic Hybridization ("aCGH") by developing microarrays that utilize discrete segments of DNA generated from the Roswell Park Cancer Institute ("RPCI") bacterial artificial chromosome ("BAC") clones. These are of considerable diagnostic value to early stage disease detection and treatment, and streamline the process by eliminating the need to grow cells or obtain large sample amounts. The company was founded on the research experience of Dr Norma Nowak and her more than 100 peer reviewed research publications. More information on Empire Genomics is available at www.empiregenomics.com. This information is provided by RNS The company news service from the London Stock Exchange END NRAEASAPEDKPEFE
1 Year Medical Solutions Chart |
1 Month Medical Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions